Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acotec Scientific HoldingsSTU:7W3 -1.47%76 ROC (Joel Greenblatt) % is 14.19% as of Dec. 2025, which is 36% above its 10-year median of 10.42. GuruFocus rates STU:7W3 with a GF Score™ of 76/100 and a GF Value™ of €1.59. The stock has 4 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Acotec Scientific Holdings ranks worse than 59.79% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Acotec Scientific Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 14.19%.
The historical rank and industry rank for Acotec Scientific Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:7W3'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -98.03 Med: 10.42 Max: 97.03
Current: -7.53
During the past 7 years, Acotec Scientific Holdings's highest ROC (Joel Greenblatt) % was 97.03%. The lowest was -98.03%. And the median was 10.42%.
STU:7W3's ROC (Joel Greenblatt) % is ranked worse than 59.79% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.615
vs STU:7W3: -7.53
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7W3 vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Acotec Scientific Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acotec Scientific Holdings ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acotec Scientific Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Acotec Scientific Holdings's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 14.19% mean?
Acotec Scientific Holdings (STU:7W3) has a ROC (Joel Greenblatt) % of 14.19% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Acotec Scientific Holdings and its competitors. This is 36% above median its historical median of 10.42. According to the industry distribution chart, Acotec Scientific Holdings ranks #501 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 59.8%.
Is Acotec Scientific Holdings' ROC (Joel Greenblatt) % too high?
Acotec Scientific Holdings' current ROC (Joel Greenblatt) % of 14.19% is 36% above median its 10-year median of 10.42. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.62. Acotec Scientific Holdings' value of 14.19% is 207.5% above this industry median. Based on the distribution chart, Acotec Scientific Holdings ranks #501 out of 838 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Acotec Scientific Holdings has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Acotec Scientific Holdings' ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acotec Scientific Holdings ranks #501 out of 838 companies for ROC (Joel Greenblatt) %. This places Acotec Scientific Holdings in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.62. Acotec Scientific Holdings' value of 14.19% is 207.5% above this benchmark. While the company's 10-year median is 10.42 vs. the industry median of 4.62, Acotec Scientific Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.62, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acotec Scientific Holdings's current ROC (Joel Greenblatt) % of 14.19% is 207.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Acotec Scientific Holdings and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acotec Scientific Holdings's current ROC (Joel Greenblatt) % is 14.19%, which is 36% above median its own 10-year median of 10.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acotec Scientific Holdings stock overvalued right now?
Acotec Scientific Holdings (STU:7W3) has a current ROC (Joel Greenblatt) % of 14.19%. The stock's GF Value™ is €1.59, compared to a current price of €0.67 — trading 57.9% below its estimated fair value. The current ROC (Joel Greenblatt) % is 14.19%, which is 36% above median its 10-year median of 10.42 and 207.5% above the Medical Devices & Instruments industry median of 4.62. Acotec Scientific Holdings' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Acotec Scientific Holdings (STU:7W3), the current ROC (Joel Greenblatt) % is 14.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acotec Scientific Holdings (STU:7W3) Overvalued in 2026?
Based on GuruFocus' analysis, Acotec Scientific Holdings stock appears to be undervalued.
The current stock price of €0.67 is trading 57.9% below its estimated GF Value™ of €1.59.
Key valuation signals for STU:7W3:
ROC (Joel Greenblatt) %: 14.19% (36% above median its 10-year median of 10.42)
GF Value™: €1.59 vs. price of €0.67 (57.9% below fair value)
Industry Position: 207.5% above the Medical Devices & Instruments median (#501 of 838)
No single metric tells the full story. See the STU:7W3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acotec Scientific Holdings Ltd is a medical technology company, focusing on the research and development, and application of technology platforms in the field of vascular interventional treatment. Its product portfolio comprises Semi-compliant PTCA balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), Coronary CTO Antegrade Micro-Catheter (Vericor-14), Coronary High-Pressure Balloon (YIYAN), Coronary CTO Retrograde Micro-Catheter (Vericor-RS), Cardiac Valve Balloon Dilation Catheter (RunFlow), etc., and also has various other products in its development pipeline. Geographically, the company generates a majority of its revenue from Mainland China, and the rest from other regions. The firm generates the majority of its revenue from sales to Domestic distributors.
76GF Score
Get the complete analysis for STU:7W3
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7W3 has been successfully added to your 
